Literature DB >> 20733939

Anti-adhesion strategies for inflammatory bowel disease.

Brian Feagan1.   

Abstract

Entities:  

Year:  2010        PMID: 20733939      PMCID: PMC2920587     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  4 in total

1.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

2.  Natalizumab induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Jean Frédéric Colombel; Roberts Enns; Brian G Feagan; Stephen B Hanauer; Ian C Lawrance; Remo Panaccione; Martin Sanders; Stefan Schreiber; Stephan Targan; Sander van Deventer; Ronald Goldblum; Darrin Despain; Gary S Hogge; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-11-03       Impact factor: 91.245

3.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Authors:  Stephan R Targan; Brian G Feagan; Richard N Fedorak; Bret A Lashner; Remo Panaccione; Daniel H Present; Martina E Spehlmann; Paul J Rutgeerts; Zsolt Tulassay; Miroslava Volfova; Douglas C Wolf; Chito Hernandez; Jeffrey Bornstein; William J Sandborn
Journal:  Gastroenterology       Date:  2007-03-21       Impact factor: 22.682

4.  Maintenance therapy with certolizumab pegol for Crohn's disease.

Authors:  Stefan Schreiber; Mani Khaliq-Kareemi; Ian C Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.